{"id":"W2806730227","doi":"10.1200/jco.2018.36.15_suppl.tps1107","title":"BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of <i>PIK3CA</i> mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2<i>–</i>) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Letrozole; Medicine; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Internal medicine; Mutant; Hormone receptor; Pharmacology; Receptor; Oncology; Endocrinology; Cancer; Estrogen receptor; Biology; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001047008,0.0007785611,0.003943603,0.0003157554,0.0002653057,0.00002041031,0.0003513181,0.000447137,0.0004165317],"category_scores_gemma":[0.0004521978,0.0004723087,0.0007383417,0.0004209795,0.001290522,0.0005027448,0.00007336203,0.0007450234,0.00000351292],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000896963,"about_ca_system_score_gemma":0.001968414,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001550676,"about_ca_topic_score_gemma":0.000344355,"domain_scores_codex":[0.9924933,0.0007939471,0.004057426,0.0008420009,0.001047574,0.0007657264],"domain_scores_gemma":[0.9888062,0.001956083,0.005330319,0.0005286824,0.002708639,0.0006700787],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4093582,0.04008477,0.005516414,0.00007962094,0.003460178,0.0004072314,0.005228405,0.00002348667,0.07002686,0.000008693278,0.0001385362,0.4656675],"study_design_scores_gemma":[0.1768591,0.6228108,0.047439,0.001276186,0.00126165,0.0004135008,0.003398286,0.00001765825,0.140814,0.0000818532,0.004954658,0.0006732739],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907134,0.001118605,0.0004122649,0.002734671,0.0008518416,0.003279165,0.0007896816,0.00003401006,0.00006633355],"genre_scores_gemma":[0.9840088,0.0008672683,0.01072587,0.0007790694,0.002962954,0.0003589323,0.0000163109,0.0001398241,0.0001409953],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5827261,"threshold_uncertainty_score":0.9997728,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06887970135663998,"score_gpt":0.4446081298824254,"score_spread":0.3757284285257854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}